Naslov
Expression and prognostic role of syndecan-2 in prostate cancer

Autori
Popović, Alek ; Demirović, Alma ; Spajić, Borislav ; Štimac, Goran ; Krušlin, Božo ; Tomas, Davor

Izvornik
Prostate cancer and prostatic diseases (1365-7852) 13 (2010), 1; 78-82

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
syndecan-2; prostate cancer; prognosis

Sažetak
Syndecans are a four-member family of transmembrane heparan sulfate proteoglycans that have different functions in cell signalling, adhesion, cytoskeleton organization, migration, proliferation and angiogenesis. Several studies investigated the role of syndecan-2 (SDC2) in different carcinomas, however, only one being focused on SDC2 in prostate cancer. SDC2 expression and relationship with established prognostic features were assessed in a cohort of 86 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. SDC2 expression was present in the majority of prostate cancers and absent in only 11.6% of cases. SDC2 expression was also recorded in cells of prostatic intraepithelial neoplasia, whereas normal prostatic epithelial tissue and stroma did not express SDC2. SDC2 overexpression in prostate cancer was significantly associated with established features indicative of worse prognosis such as higher preoperative PSA (p=0.011), higher Gleason score (p<0.001), positive surgical margins (p<0.003), and extraprostatic extension of disease (p<0.003). Moreover, expression of SDC2 was also associated with biochemical disease progression on univariate analysis (p<0.001). Study results supported the potential role of SDC2 in prostatic carcinogenesis and cancer progression. Moreover, SDC2 could serve as an additional prognostic marker that might help in further stratifying the risk of disease progression in patients with prostate cancer.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA